Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 13/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891450 | 0.83 | CCR1 (0.40) | CYP11B1CYP11B2CYP3A4TRPA1ALDH1A1 | |
| SCHEMBL29574545 | 0.83 | CCR1 (0.40) | CYP11B1CYP11B2CYP3A4TRPA1ALDH1A1 | |
| SCHEMBL9805438 | 0.82 | RAB9A (0.63) | CYP11B1CYP11B2NPC1NFKB1MAPK1 | |
| SCHEMBL8187876 | 0.81 | GRM2 (0.49) | CYP11B1CYP11B2ALDH1A1NPC1NFKB1 | |
| SCHEMBL18291876 | 0.80 | CYP11B1 (0.59) | CYP11B1CYP11B2CYP3A4LDHAHPGDS | |
| SCHEMBL20122190 | 0.80 | CYP11B1 (0.80) | CYP11B1CYP11B2CYP3A4LDHAHPGDS | |
| SCHEMBL146559 | 0.80 | NPC1 (0.65) | CYP11B1CYP11B2CYP3A4LDHANPC1 | |
| SCHEMBL2412899 | 0.80 | CYP11B1 (0.59) | CYP11B1CYP11B2CYP3A4LDHAHPGDS | |
| SCHEMBL1720975 | 0.80 | CYP11B1 (0.59) | CYP11B1CYP11B2CYP3A4LDHAHPGDS | |
| SCHEMBL2411349 | 0.80 | CYP11B1 (0.59) | CYP11B1CYP11B2CYP3A4LDHAHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4329889-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| WO-2022227015-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022232333-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2022-11-03 | — | — | WO | disclosed |
| US-11466048-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | NOVARTIS AG (CH) | 2022-10-11 | — | — | US | disclosed |
| EP-3904366-A1 | END CAPPED NUCLEIC ACID MOLECULES | Novartis AG (CH) | 2021-11-03 | — | — | EP | disclosed |
| EP-3904366-A1 | END CAPPED NUCLEIC ACID MOLECULES | Novartis AG (CH) | 2021-11-03 | — | — | EP | disclosed |
| EP-0971878-B1 | AMINE COMPOUNDS, THEIR PRODUCTION AND USE AS AMYLOID-BETA PRODUCTION INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2008-03-26 | — | — | EP | disclosed |
| US-7256204-B2 | Amine compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-14 | — | — | US | disclosed |
| US-20070176540-A1 | Transition metal complex compound and organic electroluminescence device using the compound | IDEMITSU KOSAN CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| US-20070176540-A1 | Transition metal complex compound and organic electroluminescence device using the compound | IDEMITSU KOSAN CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| US-20040077867-A1 | Amine compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| US-6613805-B2 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-02 | — | — | US | disclosed |
| US-20020032189-A1 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | THE UNIVERSITY OF TOKYO (JP) | 2002-03-14 | — | — | US | disclosed |
| US-6310107-B1 | (+)-6-(4-BIPHENYLYL)METHOXY-2-(2-(N,N-DIMETHYLAMINO)ETHYL)TETR ALIN, OR A SALT IS USEFUL FOR INHIBITING PRODUCTION AND/OR SECRETION OF AMYLOID-BETA PROTEIN | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-30 | — | — | US | disclosed |
| EP-0971878-A1 | AMINE COMPOUNDS, THEIR PRODUCTION AND USE AS AMYLOID-BETA PRODUCTION INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998038156-A1 | AMINE COMPOUNDS, THEIR PRODUCTION AND USE AS AMYLOID-BETA PRODUCTION INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | CYP11B1 4873/4885CYP11B2 4879/4885CYP3A4 4872/4885 |
| US-20020032189-A1 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | PARK7, PSEN1, PRNP | CYP11B1 2035/4885CYP11B2 2388/4885CYP3A4 4229/4885 |
| US-20070176540-A1 | Transition metal complex compound and organic electroluminescence device using the compound | TMCO1, TIMCC, EMC2 | CYP11B1 3817/4885CYP11B2 3438/4885CYP3A4 1379/4885 |
| US-20040077867-A1 | Amine compounds, their production and use | QSOX1, APP, NPR1 | CYP11B1 172/4885CYP11B2 232/4885CYP3A4 1447/4885 |
| US-11466048-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | RNGTT, NSUN3, NSUN2 | CYP11B1 4880/4885CYP11B2 4881/4885CYP3A4 4871/4885 |
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | CYP11B1 1150/4885CYP11B2 1452/4885CYP3A4 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.